Hit-and-run epigenetic editing prevents senescence entry in primary breast cells from healthy donors

Area of Science:

• Epigenetics
• Cancer Biology
• Molecular Oncology

Background:

• Aberrant promoter DNA hypermethylation is a known hallmark of cancer.
• The sufficiency of DNA hypermethylation alone to drive cellular transformation remains unclear.
• Understanding epigenetic drivers of cancer is crucial for developing targeted therapies.

Purpose of the Study:

• To investigate whether de novo DNA hypermethylation of key cancer-associated genes can drive cellular transformation.
• To determine if induced epigenetic alterations can bypass normal cellular safeguards like senescence.
• To explore the role of specific gene methylation, such as CDKN2A, in preventing senescence.

Main Methods:

• Utilized a CRISPR-dCas9 epigenetic editing tool fused to DNA methyltransferase effectors.
• Induced simultaneous de novo DNA methylation of CDKN2A, RASSF1, HIC1, and PTEN in primary human breast cells.
• Assessed the maintenance of promoter methylation and its impact on cellular phenotypes, including senescence arrest and gene expression.

Main Results:

• Successfully induced and maintained de novo DNA methylation of target genes in primary breast cells.
• Demonstrated that induced promoter methylation prevents cells from entering senescence arrest.
• Identified repression of the CDKN2A transcript (p16) as a key driver of the observed phenotype, leading to cancer-like gene expression without anchorage-independent growth.

Conclusions:

• Hit-and-run epigenetic events, such as targeted DNA hypermethylation, can prevent senescence entry.
• These epigenetic modifications may serve as early facilitators of tumor initiation.
• The study provides evidence that epigenetic alterations alone can disrupt normal cellular function and contribute to a pre-cancerous state.